1
|
Hasin N, Riggs LM, Shekhtman T, Ashworth J, Lease R, Oshone RT, Humphries EM, Badner JA, Thomson PA, Glahn DC, Craig DW, Edenberg HJ, Gershon ES, McMahon FJ, Nurnberger JI, Zandi PP, Kelsoe JR, Roach JC, Gould TD, Ament SA. Rare variants implicate NMDA receptor signaling and cerebellar gene networks in risk for bipolar disorder. Mol Psychiatry 2022; 27:3842-3856. [PMID: 35546635 DOI: 10.1038/s41380-022-01609-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/19/2021] [Revised: 04/19/2022] [Accepted: 04/28/2022] [Indexed: 02/08/2023]
Abstract
Bipolar disorder is an often-severe mental health condition characterized by alternation between extreme mood states of mania and depression. Despite strong heritability and the recent identification of 64 common variant risk loci of small effect, pathophysiological mechanisms remain unknown. Here, we analyzed genome sequences from 41 multiply-affected pedigrees and identified variants in 741 genes with nominally significant linkage or association with bipolar disorder. These 741 genes overlapped known risk genes for neurodevelopmental disorders and clustered within gene networks enriched for synaptic and nuclear functions. The top variant in this analysis - prioritized by statistical association, predicted deleteriousness, and network centrality - was a missense variant in the gene encoding D-amino acid oxidase (DAOG131V). Heterologous expression of DAOG131V in human cells resulted in decreased DAO protein abundance and enzymatic activity. In a knock-in mouse model of DAOG131, DaoG130V/+, we similarly found decreased DAO protein abundance in hindbrain regions, as well as enhanced stress susceptibility and blunted behavioral responses to pharmacological inhibition of N-methyl-D-aspartate receptors (NMDARs). RNA sequencing of cerebellar tissue revealed that DaoG130V resulted in decreased expression of two gene networks that are enriched for synaptic functions and for genes expressed, respectively, in Purkinje neurons or granule neurons. These gene networks were also down-regulated in the cerebellum of patients with bipolar disorder compared to healthy controls and were enriched for additional rare variants associated with bipolar disorder risk. These findings implicate dysregulation of NMDAR signaling and of gene expression in cerebellar neurons in bipolar disorder pathophysiology and provide insight into its genetic architecture.
Collapse
Affiliation(s)
- Naushaba Hasin
- Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Lace M Riggs
- Program in Neuroscience and Training Program in Integrative Membrane Biology, University of Maryland School of Medicine, Baltimore, MD, USA
- Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Tatyana Shekhtman
- Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
| | | | - Robert Lease
- Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA
- Program in Molecular Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Rediet T Oshone
- Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Elizabeth M Humphries
- Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA
- Program in Molecular Epidemiology, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Judith A Badner
- Department of Psychiatry, Rush University Medical College, Chicago, IL, USA
| | - Pippa A Thomson
- Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, Scotland, UK
| | - David C Glahn
- Department of Psychiatry, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA
| | - David W Craig
- Department of Translational Genomics, University of Southern California, Los Angeles, CA, USA
| | - Howard J Edenberg
- Departments of Biochemistry and Molecular Biology and Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Elliot S Gershon
- Departments of Psychiatry and Human Genetics, University of Chicago, Chicago, IL, USA
| | - Francis J McMahon
- Intramural Research Program, National Institute of Mental Health, Bethesda, MD, USA
| | - John I Nurnberger
- Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA
| | - Peter P Zandi
- Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD, USA
| | - John R Kelsoe
- Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
| | | | - Todd D Gould
- Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA
- Departments of Pharmacology and Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, USA
- Veterans Affairs Maryland Health Care System, Baltimore, MD, USA
| | - Seth A Ament
- Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA.
- Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
| |
Collapse
|
2
|
Tang H, Jensen K, Houang E, McRobb FM, Bhat S, Svensson M, Bochevarov A, Day T, Dahlgren MK, Bell JA, Frye L, Skene RJ, Lewis JH, Osborne JD, Tierney JP, Gordon JA, Palomero MA, Gallati C, Chapman RSL, Jones DR, Hirst KL, Sephton M, Chauhan A, Sharpe A, Tardia P, Dechaux EA, Taylor A, Waddell RD, Valentine A, Janssens HB, Aziz O, Bloomfield DE, Ladha S, Fraser IJ, Ellard JM. Discovery of a Novel Class of d-Amino Acid Oxidase Inhibitors Using the Schrödinger Computational Platform. J Med Chem 2022; 65:6775-6802. [PMID: 35482677 DOI: 10.1021/acs.jmedchem.2c00118] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
d-Serine is a coagonist of the N-methyl d-aspartate (NMDA) receptor, a key excitatory neurotransmitter receptor. In the brain, d-serine is synthesized from its l-isomer by serine racemase and is metabolized by the D-amino acid oxidase (DAO, DAAO). Many studies have linked decreased d-serine concentration and/or increased DAO expression and enzyme activity to NMDA dysfunction and schizophrenia. Thus, it is feasible to employ DAO inhibitors for the treatment of schizophrenia and other indications. Powered by the Schrödinger computational modeling platform, we initiated a research program to identify novel DAO inhibitors with the best-in-class properties. The program execution leveraged an hDAO FEP+ model to prospectively predict compound potency. A new class of DAO inhibitors with desirable properties has been discovered from this endeavor. Our modeling technology on this program has not only enhanced the efficiency of structure-activity relationship development but also helped to identify a previously unexplored subpocket for further optimization.
Collapse
Affiliation(s)
- Haifeng Tang
- Schrödinger Inc., New York, New York 10036, United States
| | | | - Evelyne Houang
- Schrödinger Inc., New York, New York 10036, United States
| | - Fiona M McRobb
- Schrödinger Inc., New York, New York 10036, United States
| | - Sathesh Bhat
- Schrödinger Inc., New York, New York 10036, United States
| | - Mats Svensson
- Schrödinger Inc., New York, New York 10036, United States
| | - Art Bochevarov
- Schrödinger Inc., New York, New York 10036, United States
| | - Tyler Day
- Schrödinger Inc., New York, New York 10036, United States
| | | | - Jeffery A Bell
- Schrödinger Inc., New York, New York 10036, United States
| | - Leah Frye
- Schrödinger Inc., New York, New York 10036, United States
| | - Robert J Skene
- Takeda Development Center Americas, Inc., San Diego, California 92121, United States
| | - James H Lewis
- Charles River Laboratories, Saffron Walden, Essex CB10 1XL, U.K
| | - James D Osborne
- Charles River Laboratories, Saffron Walden, Essex CB10 1XL, U.K
| | - Jason P Tierney
- Charles River Laboratories, Saffron Walden, Essex CB10 1XL, U.K
| | - James A Gordon
- Charles River Laboratories, Saffron Walden, Essex CB10 1XL, U.K
| | | | | | | | - Daniel R Jones
- Charles River Laboratories, Saffron Walden, Essex CB10 1XL, U.K
| | - Kim L Hirst
- Charles River Laboratories, Saffron Walden, Essex CB10 1XL, U.K
| | - Mark Sephton
- Charles River Laboratories, Saffron Walden, Essex CB10 1XL, U.K
| | - Alka Chauhan
- Charles River Laboratories, Saffron Walden, Essex CB10 1XL, U.K
| | - Andrew Sharpe
- Charles River Laboratories, Saffron Walden, Essex CB10 1XL, U.K
| | - Piero Tardia
- Charles River Laboratories, Saffron Walden, Essex CB10 1XL, U.K
| | | | - Andrea Taylor
- Charles River Laboratories, Harlow, Essex CM19 5TR, U.K
| | | | | | - Holden B Janssens
- Charles River Laboratories, South San Francisco, California 94080, United States
| | - Omar Aziz
- Charles River Laboratories, Harlow, Essex CM19 5TR, U.K
| | | | - Sandeep Ladha
- Charles River Laboratories, Saffron Walden, Essex CB10 1XL, U.K
| | - Ian J Fraser
- Charles River Laboratories, Saffron Walden, Essex CB10 1XL, U.K
| | - John M Ellard
- Charles River Laboratories, Saffron Walden, Essex CB10 1XL, U.K.,Charles River Laboratories, Harlow, Essex CM19 5TR, U.K
| |
Collapse
|
3
|
D-Amino Acids as a Biomarker in Schizophrenia. Diseases 2022; 10:diseases10010009. [PMID: 35225861 PMCID: PMC8883943 DOI: 10.3390/diseases10010009] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/27/2021] [Revised: 01/28/2022] [Accepted: 01/28/2022] [Indexed: 02/04/2023] Open
Abstract
D-amino acids may play key roles for specific physiological functions in different organs including the brain. Importantly, D-amino acids have been detected in several neurological disorders such as schizophrenia, amyotrophic lateral sclerosis, and age-related disorders, reflecting the disease conditions. Relationships between D-amino acids and neurophysiology may involve the significant contribution of D-Serine or D-Aspartate to the synaptic function, including neurotransmission and synaptic plasticity. Gut-microbiota could play important roles in the brain-function, since bacteria in the gut provide a significant contribution to the host pool of D-amino acids. In addition, the alteration of the composition of the gut microbiota might lead to schizophrenia. Furthermore, D-amino acids are known as a physiologically active substance, constituting useful biomarkers of several brain disorders including schizophrenia. In this review, we wish to provide an outline of the roles of D-amino acids in brain health and neuropsychiatric disorders with a focus on schizophrenia, which may shed light on some of the superior diagnoses and/or treatments of schizophrenia.
Collapse
|
4
|
Lei X, Lampiri P, Patil P, Angeli G, Neochoritis CG, Dömling A. A multicomponent tetrazolo indole synthesis. Chem Commun (Camb) 2021; 57:6652-6655. [PMID: 34128009 PMCID: PMC8259579 DOI: 10.1039/d1cc02384e] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The ubiquitous presence of the indole fragment in natural products and drugs asks for ever novel syntheses. We report an unprecedented mild, two-step synthesis of 2-tetrazolo substituted indoles based on the Ugi-tetrazole reaction combined with an acidic ring closure. A gram-scale synthesis, a bioactive compound and further transformations were performed. A short, diverse, and scalable Ugi synthesis towards the bioactive tetrazolo indoles.![]()
Collapse
Affiliation(s)
- Xiaofang Lei
- University of Crete, Department of Chemistry, Heraklion, Greece. and University of Groningen, Department of Pharmacy, Drug Design group, Groningen, The Netherlands.
| | | | - Pravin Patil
- University of Groningen, Department of Pharmacy, Drug Design group, Groningen, The Netherlands.
| | - Giasemi Angeli
- University of Crete, Department of Chemistry, Heraklion, Greece.
| | | | - Alexander Dömling
- University of Groningen, Department of Pharmacy, Drug Design group, Groningen, The Netherlands.
| |
Collapse
|
5
|
Zanakhov TO, Galenko EE, Kryukova MA, Novikov MS, Khlebnikov AA. Isomerization of 5-(2 H-Azirin-2-yl)oxazoles: An Atom-Economic Approach to 4 H-Pyrrolo[2,3- d]oxazoles. Molecules 2021; 26:molecules26071881. [PMID: 33810476 PMCID: PMC8036974 DOI: 10.3390/molecules26071881] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2021] [Revised: 03/19/2021] [Accepted: 03/23/2021] [Indexed: 11/16/2022] Open
Abstract
An atom economical method for the preparation of variously substituted 4H-pyrrolo[2,3-d]oxazoles was developed on the basis of thermal isomerization of 5-(2H-azirin-2-yl)oxazoles. The latter were prepared by Rh2(oct)4 catalyzed reaction of 2-(3-aryl/heteroaryl)-2-diazoacetyl-2H-azirines with a set of substituted acetonitriles, benzonitriles, acrylonitrile and fumaronitrile. According to DFT calculations the transformation of 5-(2H-azirin-2-yl)oxazole to 4H-pyrrolo[2,3-d]oxazole occurs through the nitrenoid-like transition state to give a 3aH-pyrrolo[2,3-d]oxazole intermediate, followed by 1,5-H-shift.
Collapse
|
6
|
Radaelli A, Gruetter R, Yoshihara HAI. In vivo detection of d-amino acid oxidase with hyperpolarized d-[1- 13 C]alanine. NMR IN BIOMEDICINE 2020; 33:e4303. [PMID: 32325540 DOI: 10.1002/nbm.4303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/14/2019] [Revised: 02/19/2020] [Accepted: 03/07/2020] [Indexed: 06/11/2023]
Abstract
d-amino acid oxidase (DAO) is a peroxisomal enzyme that catalyzes the oxidative deamination of several neutral and basic d-amino acids to their corresponding α-keto acids. In most mammalian species studied, high DAO activity is found in the kidney, liver, brain and polymorphonuclear leukocytes, and its main function is to maintain low circulating d-amino acid levels. DAO expression and activity have been associated with acute and chronic kidney diseases and with several pathologies related to N-methyl-d-aspartate (NMDA) receptor hypo/hyper-function; however, its precise role is not completely understood. In the present study we show that DAO activity can be detected in vivo in the rat kidney using hyperpolarized d-[1-13 C]alanine. Following a bolus of hyperpolarized d-alanine, accumulation of pyruvate, lactate and bicarbonate was observed only when DAO activity was not inhibited. The measured lactate-to-d-alanine ratio was comparable to the values measured when the l-enantiomer was injected. Metabolites downstream of DAO were not observed when scanning the liver and brain. The conversion of hyperpolarized d-[1-13 C]alanine to lactate and pyruvate was detected in blood ex vivo, and lactate and bicarbonate were detected on scanning the blood pool in the heart in vivo; however, the bicarbonate-to-d-alanine ratio was significantly lower compared with the kidney. These results demonstrate that the specific metabolism of the two enantiomers of hyperpolarized [1-13 C]alanine in the kidney and in the blood can be distinguished, underscoring the potential of d-[1-13 C]alanine as a probe of d-amino acid metabolism.
Collapse
Affiliation(s)
- Alice Radaelli
- Laboratory for Functional and Metabolic Imaging (LIFMET), École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Rolf Gruetter
- Laboratory for Functional and Metabolic Imaging (LIFMET), École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - Hikari A I Yoshihara
- Laboratory for Functional and Metabolic Imaging (LIFMET), École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| |
Collapse
|
7
|
Liu H, Zhao M, Wang Z, Han Q, Wu H, Mao X, Wang Y. Involvement of d-amino acid oxidase in cerebral ischaemia induced by transient occlusion of the middle cerebral artery in mice. Br J Pharmacol 2019; 176:3336-3349. [PMID: 31309542 PMCID: PMC6692583 DOI: 10.1111/bph.14764] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2018] [Revised: 05/03/2019] [Accepted: 05/16/2019] [Indexed: 01/01/2023] Open
Abstract
BACKGROUND AND PURPOSE d-Amino acid oxidase (DAAO) is a flavine adenine dinucleotide-containing flavoenzyme and specifically catalyses oxidative deamination of d-amino acids. This study aimed to explore the association between increased cerebral DAAO expression or enzymic activity and the development of cerebral ischaemia. EXPERIMENTAL APPROACH A mouse model of transient (90 min) middle cerebral artery occlusion (MCAO) was established, and western blotting, enzymic activity assay, and fluorescent immunostaining techniques were used. KEY RESULTS The expression and enzymic activity of DAAO increased over time in the cortical peri-infarct area of the mice subjected to transient MCAO. The DAAO was specifically expressed in astrocytes, and its double immunostaining with the astrocytic intracellular marker, glial fibrillary acidic protein, in the cortical peri-infarct area was up-regulated following ischaemic insult, with peak increase on Day 5 after MCAO. Single intravenous injection of the specific and potent DAAO inhibitor Compound SUN reduced the cerebral DAAO enzymic activity and attenuated neuronal infarction and neurobehavioural deficits with optimal improvement apparent immediately after the MCAO procedure. The neuroprotective effect was dose dependent, with ED50 values of 3.9-4.5 mg·kg-1 . Intracerebroventricular injection of the DAAO gene silencer siRNA/DAAO significantly reduced cerebral DAAO expression and attenuated MCAO-induced neuronal infarction and behavioural deficits. CONCLUSIONS AND IMPLICATIONS Our results, for the first time, demonstrated that increased cerebral astrocytic DAAO expression and enzymic activity were causally associated with the development of neuronal destruction following ischaemic insults, suggesting that targeting cerebral DAAO could be a potential approach for treatment of neurological conditions following cerebral ischaemia.
Collapse
Affiliation(s)
- Hao Liu
- King's LabShanghai Jiao Tong University School of PharmacyShanghaiChina
| | - Meng‐Jing Zhao
- King's LabShanghai Jiao Tong University School of PharmacyShanghaiChina
| | - Zi‐Ying Wang
- King's LabShanghai Jiao Tong University School of PharmacyShanghaiChina
| | - Qiao‐Qiao Han
- King's LabShanghai Jiao Tong University School of PharmacyShanghaiChina
| | - Hai‐Yun Wu
- King's LabShanghai Jiao Tong University School of PharmacyShanghaiChina
| | - Xiao‐fang Mao
- King's LabShanghai Jiao Tong University School of PharmacyShanghaiChina
| | - Yong‐Xiang Wang
- King's LabShanghai Jiao Tong University School of PharmacyShanghaiChina
| |
Collapse
|
8
|
Grozav AN, Fedoriv MZ, Chornous VA, Palamar AA, Bratenko MK, Vovk MV. Synthesis of thieno[2,3-b]pyrrole-2(4)-carboxylic and 2,4-dicarboxylic acids. Chem Heterocycl Compd (N Y) 2019. [DOI: 10.1007/s10593-019-02476-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
9
|
Padhi AK, Hazra S. Insights into the role of d-amino acid oxidase mutations in amyotrophic lateral sclerosis. J Cell Biochem 2019; 120:2180-2197. [PMID: 30206963 DOI: 10.1002/jcb.27529] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2018] [Accepted: 08/01/2018] [Indexed: 01/24/2023]
Abstract
Missense mutations in the coding region of d-amino acid oxidase (DAO) have been found in patients suffering from amyotrophic lateral sclerosis (ALS). Mutations primarily impair the enzymatic activity of DAO and cause neurodegeneration due to an abnormal accumulation of d-serine in the spinal cord. However, the structural and dynamic changes that lead to impaired enzymatic activity are not fully understood. We present here extensive molecular dynamics simulations of wild-type, and all reported ALS-associated DAO mutants to elucidate the plausible mechanisms of impaired enzymatic activity, a critical function needed for neuroprotection. Simulation results show that DAO mutations disrupt several key interactions with the active site residues and decrease the conformational flexibility of active site loop comprising 216 to 228 residues, necessary for substrate binding and product release. This conformational restriction of the active site loop in the mutants is mainly due to the distortion of critical salt bridge and hydrogen bond interactions compared with wild-type. Furthermore, binding free energy calculations show that DAO mutants have a lower binding affinity toward cofactor flavin adenine dinucleotide and substrate imino-serine than the wild-type. A closer look at the cofactor and substrate interaction profiles further show that DAO mutants have lost several critical interactions with the neighboring residues as compared with wild-type. Taken together, this study provides first-hand explanation of crucial structural features that lead to the loss of enzymatic function in DAO mutants and highlights the need of further genomic scans of patients with ALS to map the association of novel DAO variants in ALS pathophysiology.
Collapse
Affiliation(s)
- Aditya K Padhi
- Laboratory for Structural Bioinformatics, Field for Structural Molecular Biology, RIKEN Center for Biosystems Dynamics Research, Yokohama, Japan
| | - Saugata Hazra
- Department of Biotechnology, Indian Institute of Technology Roorkee, Roorkee, India.,Center of Nanotechnology, Indian Institute of Technology Roorkee, Roorkee, India
| |
Collapse
|
10
|
Szilágyi B, Hargitai C, Kelemen ÁA, Rácz A, Ferenczy GG, Volk B, Keserű GM. Synthesis and Biochemical Evaluation of Lid-Open D-Amino Acid Oxidase Inhibitors. Molecules 2019; 24:molecules24020290. [PMID: 30646619 PMCID: PMC6358909 DOI: 10.3390/molecules24020290] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2018] [Revised: 01/07/2019] [Accepted: 01/10/2019] [Indexed: 11/30/2022] Open
Abstract
Most of the known inhibitors of d-amino acid oxidase (DAAO) are small polar molecules recognized by the active site of the enzyme. More recently a new class of DAAO inhibitors has been disclosed that interacts with loop 218−224 at the top of the binding pocket. These compounds have a significantly larger size and more beneficial physicochemical properties than most reported DAAO inhibitors, however, their structure-activity relationship is poorly explored. Here we report the synthesis and evaluation of this type of DAAO inhibitors that open the lid over the active site of DAAO. In order to collect relevant SAR data we varied two distinct parts of the inhibitors. A systematic variation of the pendant aromatic substituents according to the Topliss scheme resulted in DAAO inhibitors with low nanomolar activity. The activity showed low sensitivity to the substituents investigated. The variation of the linker connecting the pendant aromatic moiety and the acidic headgroup revealed that the interactions of the linker with the enzyme were crucial for achieving significant inhibitory activity. Structures and activities were analyzed based on available X-ray structures of the complexes. Our findings might support the design of drug-like DAAO inhibitors with advantageous physicochemical properties and ADME profile.
Collapse
Affiliation(s)
- Bence Szilágyi
- Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudósok krt. 2, H-1117 Budapest, Hungary.
| | - Csilla Hargitai
- Directorate of Drug Substance Development, Egis Pharmaceuticals Plc., P.O. Box 100, H-1475 Budapest, Hungary.
| | - Ádám A Kelemen
- Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudósok krt. 2, H-1117 Budapest, Hungary.
| | - Anita Rácz
- Plasma Chemistry Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudósok krt. 2, H-1117 Budapest, Hungary.
| | - György G Ferenczy
- Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudósok krt. 2, H-1117 Budapest, Hungary.
| | - Balázs Volk
- Directorate of Drug Substance Development, Egis Pharmaceuticals Plc., P.O. Box 100, H-1475 Budapest, Hungary.
| | - György M Keserű
- Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudósok krt. 2, H-1117 Budapest, Hungary.
| |
Collapse
|
11
|
Kato Y, Hin N, Maita N, Thomas AG, Kurosawa S, Rojas C, Yorita K, Slusher BS, Fukui K, Tsukamoto T. Structural basis for potent inhibition of d-amino acid oxidase by thiophene carboxylic acids. Eur J Med Chem 2018; 159:23-34. [PMID: 30265959 PMCID: PMC6193832 DOI: 10.1016/j.ejmech.2018.09.040] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2018] [Revised: 07/10/2018] [Accepted: 09/14/2018] [Indexed: 12/15/2022]
Abstract
A series of thiophene-2-carboxylic acids and thiophene-3-carboxylic acids were identified as a new class of DAO inhibitors. Structure-activity relationship (SAR) studies revealed that small substituents are well-tolerated on the thiophene ring of both the 2-carboxylic acid and 3-carboxylic acid scaffolds. Crystal structures of human DAO in complex with potent thiophene carboxylic acids revealed that Tyr224 was tightly stacked with the thiophene ring of the inhibitors, resulting in the disappearance of the secondary pocket observed with other DAO inhibitors. Molecular dynamics simulations of the complex revealed that Tyr224 preferred the stacked conformation irrespective of whether Tyr224 was stacked or not in the initial state of the simulations. MM/GBSA indicated a substantial hydrophobic interaction between Tyr244 and the thiophene-based inhibitor. In addition, the active site was tightly closed with an extensive network of hydrogen bonds including those from Tyr224 in the stacked conformation. The introduction of a large branched side chain to the thiophene ring markedly decreased potency. These results are in marked contrast to other DAO inhibitors that can gain potency with a branched side chain extending to the secondary pocket due to Tyr224 repositioning. These insights should be of particular importance in future efforts to optimize DAO inhibitors with novel scaffolds.
Collapse
Affiliation(s)
- Yusuke Kato
- Institute for Enzyme Research, Tokushima University, Tokushima, 770-8503, Japan
| | - Niyada Hin
- Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, 21205, USA
| | - Nobuo Maita
- Institute for Enzyme Research, Tokushima University, Tokushima, 770-8503, Japan
| | - Ajit G Thomas
- Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, 21205, USA
| | - Sumire Kurosawa
- Institute for Enzyme Research, Tokushima University, Tokushima, 770-8503, Japan
| | - Camilo Rojas
- Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, 21205, USA
| | - Kazuko Yorita
- Institute for Enzyme Research, Tokushima University, Tokushima, 770-8503, Japan
| | - Barbara S Slusher
- Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, 21205, USA; Department of Neurology, Johns Hopkins University, Baltimore, MD, 21205, USA
| | - Kiyoshi Fukui
- Institute for Enzyme Research, Tokushima University, Tokushima, 770-8503, Japan.
| | - Takashi Tsukamoto
- Johns Hopkins Drug Discovery, Johns Hopkins University, Baltimore, MD, 21205, USA; Department of Neurology, Johns Hopkins University, Baltimore, MD, 21205, USA
| |
Collapse
|
12
|
Bernetti M, Rosini E, Mollica L, Masetti M, Pollegioni L, Recanatini M, Cavalli A. Binding Residence Time through Scaled Molecular Dynamics: A Prospective Application to hDAAO Inhibitors. J Chem Inf Model 2018; 58:2255-2265. [DOI: 10.1021/acs.jcim.8b00518] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Affiliation(s)
- Mattia Bernetti
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum − Università di Bologna, Via Belmeloro 6, 40126, Bologna, Italy
- Computational and Chemical Biology, Istituto Italiano di Tecnologia, Via Morego 30, 16163, Genova, Italy
| | - Elena Rosini
- Department of Biotechnology and Life Sciences, Università degli Studi dell’Insubria, Via J.H. Dunant 3, 21100, Varese, Italy
| | - Luca Mollica
- Istituto Nazionale Genetica Molecolare “Romeo ed Enrica Invernizzi″, Via F. Sforza 35, Milan, 20122, Italy
- Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Milano 20129, Italy
| | - Matteo Masetti
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum − Università di Bologna, Via Belmeloro 6, 40126, Bologna, Italy
| | - Loredano Pollegioni
- Department of Biotechnology and Life Sciences, Università degli Studi dell’Insubria, Via J.H. Dunant 3, 21100, Varese, Italy
| | - Maurizio Recanatini
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum − Università di Bologna, Via Belmeloro 6, 40126, Bologna, Italy
| | - Andrea Cavalli
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum − Università di Bologna, Via Belmeloro 6, 40126, Bologna, Italy
- Computational and Chemical Biology, Istituto Italiano di Tecnologia, Via Morego 30, 16163, Genova, Italy
| |
Collapse
|
13
|
Ball J, Gannavaram S, Gadda G. Structural determinants for substrate specificity of flavoenzymes oxidizing d-amino acids. Arch Biochem Biophys 2018; 660:87-96. [PMID: 30312594 DOI: 10.1016/j.abb.2018.10.002] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Revised: 10/01/2018] [Accepted: 10/08/2018] [Indexed: 12/26/2022]
Abstract
The oxidation of d-amino acids is relevant to neurodegenerative diseases, detoxification, and nutrition in microorganisms and mammals. It is also important for the resolution of racemic amino acid mixtures and the preparation of chiral building blocks for the pharmaceutical and food industry. Considerable biochemical and structural knowledge has been accrued in recent years on the enzymes that carry out the oxidation of the Cα-N bond of d-amino acids. These enzymes contain FAD as a required coenzyme, share similar overall three-dimensional folds and highly conserved active sites, but differ in their specificity for substrates with neutral, anionic, or cationic side-chains. Here, we summarize the current biochemical and structural knowledge regarding substrate specificity on d-amino acid oxidase, d-aspartate oxidase, and d-arginine dehydrogenase for which a wealth of biochemical and structural studies is available.
Collapse
Affiliation(s)
- Jacob Ball
- Departments of Chemistry, Georgia State University, Atlanta, GA, 30302-3965, USA
| | - Swathi Gannavaram
- Departments of Chemistry, Georgia State University, Atlanta, GA, 30302-3965, USA
| | - Giovanni Gadda
- Departments of Chemistry, Georgia State University, Atlanta, GA, 30302-3965, USA; Departments of Biology, Georgia State University, Atlanta, GA, 30302-3965, USA; Center for Biotechnology and Drug Design, Georgia State University, Atlanta, GA, 30302-3965, USA; Center for Diagnostics and Therapeutics, Georgia State University, Atlanta, GA, 30302-3965, USA.
| |
Collapse
|
14
|
Szilágyi B, Ferenczy GG, Keserű GM. Drug discovery strategies and the preclinical development of D-amino-acid oxidase inhibitors as antipsychotic therapies. Expert Opin Drug Discov 2018; 13:973-982. [DOI: 10.1080/17460441.2018.1524459] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- Bence Szilágyi
- Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary
| | - György G. Ferenczy
- Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary
| | - György M. Keserű
- Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Budapest, Hungary
| |
Collapse
|
15
|
Szilágyi B, Kovács P, Ferenczy GG, Rácz A, Németh K, Visy J, Szabó P, Ilas J, Balogh GT, Monostory K, Vincze I, Tábi T, Szökő É, Keserű GM. Discovery of isatin and 1H-indazol-3-ol derivatives as d-amino acid oxidase (DAAO) inhibitors. Bioorg Med Chem 2018; 26:1579-1587. [DOI: 10.1016/j.bmc.2018.02.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2017] [Revised: 01/27/2018] [Accepted: 02/03/2018] [Indexed: 01/23/2023]
|
16
|
Orgován Z, Ferenczy GG, Steinbrecher T, Szilágyi B, Bajusz D, Keserű GM. Validation of tautomeric and protomeric binding modes by free energy calculations. A case study for the structure based optimization of D-amino acid oxidase inhibitors. J Comput Aided Mol Des 2018; 32:331-345. [PMID: 29335871 DOI: 10.1007/s10822-018-0097-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2017] [Accepted: 01/06/2018] [Indexed: 01/16/2023]
Abstract
Optimization of fragment size D-amino acid oxidase (DAAO) inhibitors was investigated using a combination of computational and experimental methods. Retrospective free energy perturbation (FEP) calculations were performed for benzo[d]isoxazole derivatives, a series of known inhibitors with two potential binding modes derived from X-ray structures of other DAAO inhibitors. The good agreement between experimental and computed binding free energies in only one of the hypothesized binding modes strongly support this bioactive conformation. Then, a series of 1-H-indazol-3-ol derivatives formerly not described as DAAO inhibitors was investigated. Binding geometries could be reliably identified by structural similarity to benzo[d]isoxazole and other well characterized series and FEP calculations were performed for several tautomers of the deprotonated and protonated compounds since all these forms are potentially present owing to the experimental pKa values of representative compounds in the series. Deprotonated compounds are proposed to be the most important bound species owing to the significantly better agreement between their calculated and measured affinities compared to the protonated forms. FEP calculations were also used for the prediction of the affinities of compounds not previously tested as DAAO inhibitors and for a comparative structure-activity relationship study of the benzo[d]isoxazole and indazole series. Selected indazole derivatives were synthesized and their measured binding affinity towards DAAO was in good agreement with FEP predictions.
Collapse
Affiliation(s)
- Zoltán Orgován
- Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudósok krt. 2, Budapest, 1117, Hungary
| | - György G Ferenczy
- Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudósok krt. 2, Budapest, 1117, Hungary
| | | | - Bence Szilágyi
- Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudósok krt. 2, Budapest, 1117, Hungary
| | - Dávid Bajusz
- Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudósok krt. 2, Budapest, 1117, Hungary
| | - György M Keserű
- Medicinal Chemistry Research Group, Research Centre for Natural Sciences, Hungarian Academy of Sciences, Magyar tudósok krt. 2, Budapest, 1117, Hungary.
| |
Collapse
|
17
|
Molla G. Competitive Inhibitors Unveil Structure/Function Relationships in Human D-Amino Acid Oxidase. Front Mol Biosci 2017; 4:80. [PMID: 29250527 PMCID: PMC5715370 DOI: 10.3389/fmolb.2017.00080] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2017] [Accepted: 11/13/2017] [Indexed: 02/02/2023] Open
Abstract
D-amino acid oxidase (DAAO) catalyzes the oxidative deamination of several neutral D-amino acids and is the enzyme mainly responsible (together with serine racemase) for degrading D-serine (D-Ser) in the central nervous system of mammals. This D-amino acid, which binds the coagonist site of the N-methyl-D-aspartate receptor, is thus a key neuromodulator of glutamatergic neurotransmission. Altered D-Ser metabolism results in several pathological conditions (e.g., amylotrophic lateral sclerosis or schizophrenia, SZ) for which effective "broad spectrum" pharmaceutical drugs are not yet available. In particular, the correlation between reduced D-Ser concentration and SZ led to a renaissance of biochemical interest in human DAAO (hDAAO). In the last 10 years, public and corporate research laboratories undertook huge efforts to study the structural, enzymatic, and physiological properties of the human flavoenzyme and to identify novel effective inhibitors which, acting as pharmaceutical drugs, could decrease hDAAO activity, thus restoring the physiological concentration of D-Ser. Although, none of the identified hDAAO inhibitors has reached the market yet, from a biochemical point of view, these compounds turned out to be invaluable for gaining a detailed understanding of the structure/function relationships at the molecular level in the mammalian DAAO, in particular of the interaction between ligand and the enzyme. This detailed knowledge, together with several recent studies concerning the interaction of the human enzyme with other protein regulative partners, its subcellular localization, and in vivo degradation, contributed to gaining comprehensive knowledge of the structure, function, and physiopathological role of this important human enzyme.
Collapse
Affiliation(s)
- Gianluca Molla
- Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.,The Protein Factory Research Center, Politecnico of Milano and University of Insubria, Milan, Italy
| |
Collapse
|
18
|
Howley E, Bestwick M, Fradley R, Harrison H, Leveridge M, Okada K, Fieldhouse C, Farnaby W, Canning H, Sykes AP, Merchant K, Hazel K, Kerr C, Kinsella N, Walsh L, Livermore DG, Hoffman I, Ellery J, Mitchell P, Patel T, Carlton M, Barnes M, Miller DJ. Assessment of the Target Engagement and D-Serine Biomarker Profiles of the D-Amino Acid Oxidase Inhibitors Sodium Benzoate and PGM030756. Neurochem Res 2017; 42:3279-3288. [PMID: 28780732 DOI: 10.1007/s11064-017-2367-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2017] [Revised: 07/20/2017] [Accepted: 07/24/2017] [Indexed: 11/30/2022]
Abstract
Irregular N-methyl-D-aspartate receptor (NMDAR) function is one of the main hypotheses employed to facilitate understanding of the underlying disease state of schizophrenia. Although direct agonism of the NMDAR has not yielded promising therapeutics, advances have been made by modulating the NMDAR co-agonist site which is activated by glycine and D-serine. One approach to activate the co-agonist site is to increase synaptic D-serine levels through inhibition of D-amino acid oxidase (DAO), the major catabolic clearance pathway for this and other D-amino acids. A number of DAO inhibitors have been developed but most have not entered clinical trials. One exception to this is sodium benzoate which has demonstrated efficacy in small trials of schizophrenia and Alzheimer's disease. Herein we provide data on the effect of sodium benzoate and an optimised Takeda compound, PGM030756 on ex vivo DAO enzyme occupancy and cerebellar D-serine levels in mice. Both compounds achieve high levels of enzyme occupancy; although lower doses of PGM030756 (1, 3 and 10 mg/kg) were required to achieve this compared to sodium benzoate (300, 1000 mg/kg). Cerebellar D-serine levels were increased by both agents with a delay of approximately 6 h after dosing before the peak effect was achieved. Our data and methods may be useful in understanding the effects of sodium benzoate that have been seen in clinical trials of schizophrenia and Alzheimer's disease and to support the potential clinical assessment of other DAO inhibitors, such as PGM030756, which demonstrate good enzyme occupancy and D-serine increases following administration of low oral doses.
Collapse
Affiliation(s)
- Eimear Howley
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| | - Michael Bestwick
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| | - Rosa Fradley
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK.
| | - Helen Harrison
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| | - Mathew Leveridge
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| | - Kengo Okada
- Biomolecular Research Laboratories, Shonan Research Center, Takeda Pharmaceutical Company Ltd, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 25108555, Japan
| | - Charlotte Fieldhouse
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| | - Will Farnaby
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| | - Hannah Canning
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| | - Andy P Sykes
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| | - Kevin Merchant
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| | - Katherine Hazel
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| | - Catrina Kerr
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| | - Natasha Kinsella
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| | - Louise Walsh
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| | - David G Livermore
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| | - Isaac Hoffman
- Takeda California Inc., 10410 Science Center Dr, San Diego, CA, 92121, USA
| | - Jonathan Ellery
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| | - Phillip Mitchell
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| | - Toshal Patel
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| | - Mark Carlton
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| | - Matt Barnes
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| | - David J Miller
- Takeda Cambridge Ltd, 418 Cambridge Science Park, Milton Road, Cambridge, Cambridgeshire, CB4 0PA, UK
| |
Collapse
|
19
|
Kohiki T, Kato Y, Nishikawa Y, Yorita K, Sagawa I, Denda M, Inokuma T, Shigenaga A, Fukui K, Otaka A. Elucidation of inhibitor-binding pockets ofd-amino acid oxidase using docking simulation and N-sulfanylethylanilide-based labeling technology. Org Biomol Chem 2017; 15:5289-5297. [DOI: 10.1039/c7ob00633k] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Binding pockets of a schizophrenia-relatedd-amino acid oxidase to its inhibitor were clarified by docking simulation and protein labeling experiments.
Collapse
Affiliation(s)
- Taiki Kohiki
- Institute of Biomedical Sciences and Graduate School of Pharmaceutical Sciences
- Tokushima University
- Tokushima 770-8505
- Japan
| | - Yusuke Kato
- Division of Enzyme Pathophysiology
- The Institute for Enzyme Research (KOSOKEN)
- Tokushima University
- Tokushima 770-8503
- Japan
| | - Yusuke Nishikawa
- Institute of Biomedical Sciences and Graduate School of Pharmaceutical Sciences
- Tokushima University
- Tokushima 770-8505
- Japan
| | - Kazuko Yorita
- Division of Enzyme Pathophysiology
- The Institute for Enzyme Research (KOSOKEN)
- Tokushima University
- Tokushima 770-8503
- Japan
| | - Ikuko Sagawa
- Support Center for Advanced Medical Sciences
- Institute of Biomedical Sciences
- Tokushima University Graduate School
- Tokushima 770-8505
- Japan
| | - Masaya Denda
- Institute of Biomedical Sciences and Graduate School of Pharmaceutical Sciences
- Tokushima University
- Tokushima 770-8505
- Japan
| | - Tsubasa Inokuma
- Institute of Biomedical Sciences and Graduate School of Pharmaceutical Sciences
- Tokushima University
- Tokushima 770-8505
- Japan
| | - Akira Shigenaga
- Institute of Biomedical Sciences and Graduate School of Pharmaceutical Sciences
- Tokushima University
- Tokushima 770-8505
- Japan
- PRESTO
| | - Kiyoshi Fukui
- Division of Enzyme Pathophysiology
- The Institute for Enzyme Research (KOSOKEN)
- Tokushima University
- Tokushima 770-8503
- Japan
| | - Akira Otaka
- Institute of Biomedical Sciences and Graduate School of Pharmaceutical Sciences
- Tokushima University
- Tokushima 770-8505
- Japan
| |
Collapse
|
20
|
Discovery and analgesic evaluation of 8-chloro-1,4-dihydropyrido[2,3- b ]pyrazine-2,3-dione as a novel potent d -amino acid oxidase inhibitor. Eur J Med Chem 2016; 117:19-32. [DOI: 10.1016/j.ejmech.2016.04.017] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2014] [Revised: 04/05/2016] [Accepted: 04/06/2016] [Indexed: 01/10/2023]
|
21
|
Toguchi S, Hirose T, Yorita K, Fukui K, Sharpless KB, Ōmura S, Sunazuka T. In Situ Click Chemistry for the Identification of a Potent D-Amino Acid Oxidase Inhibitor. Chem Pharm Bull (Tokyo) 2016; 64:695-703. [DOI: 10.1248/cpb.c15-00867] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Shohei Toguchi
- Graduate School of Infection Control Sciences, Kitasato University
| | - Tomoyasu Hirose
- Graduate School of Infection Control Sciences, Kitasato University
- The Kitasato Institute for Life Sciences, Kitasato University
| | | | | | | | - Satoshi Ōmura
- The Kitasato Institute for Life Sciences, Kitasato University
| | - Toshiaki Sunazuka
- Graduate School of Infection Control Sciences, Kitasato University
- The Kitasato Institute for Life Sciences, Kitasato University
| |
Collapse
|
22
|
Affiliation(s)
- Su Jin Han
- Department of Chemistry and
Chemistry Institute of Functional Materials, Pusan National University, Busan 46241, Republic of Korea
| | - Hyun Tae Kim
- Department of Chemistry and
Chemistry Institute of Functional Materials, Pusan National University, Busan 46241, Republic of Korea
| | - Jung Min Joo
- Department of Chemistry and
Chemistry Institute of Functional Materials, Pusan National University, Busan 46241, Republic of Korea
| |
Collapse
|
23
|
Hin N, Duvall B, Ferraris D, Alt J, Thomas AG, Rais R, Rojas C, Wu Y, Wozniak K, Slusher BS, Tsukamoto T. 6-Hydroxy-1,2,4-triazine-3,5(2H,4H)-dione Derivatives as Novel D-Amino Acid Oxidase Inhibitors. J Med Chem 2015; 58:7258-72. [PMID: 26309148 PMCID: PMC5003509 DOI: 10.1021/acs.jmedchem.5b00482] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2015] [Indexed: 02/04/2023]
Abstract
A series of 2-substituted 6-hydroxy-1,2,4-triazine-3,5(2H,4H)-dione derivatives were synthesized as inhibitors of D-amino acid oxidase (DAAO). Many compounds in this series were found to be potent DAAO inhibitors, with IC50 values in the double-digit nanomolar range. The 6-hydroxy-1,2,4-triazine-3,5(2H,4H)-dione pharmacophore appears metabolically resistant to O-glucuronidation unlike other structurally related DAAO inhibitors. Among them, 6-hydroxy-2-(naphthalen-1-ylmethyl)-1,2,4-triazine-3,5(2H,4H)-dione 11h was found to be selective over a number of targets and orally available in mice. Furthermore, oral coadministration of D-serine with 11h enhanced the plasma levels of D-serine in mice compared to the oral administration of D-serine alone, demonstrating its ability to serve as a pharmacoenhancer of D-serine.
Collapse
Affiliation(s)
- Niyada Hin
- Brain Science Institute, Department of Neurology, and Department of
Molecular and Comparative
Pathobiology, Johns Hopkins University, Baltimore, Maryland 21205, United States
| | - Bridget Duvall
- Brain Science Institute, Department of Neurology, and Department of
Molecular and Comparative
Pathobiology, Johns Hopkins University, Baltimore, Maryland 21205, United States
| | - Dana Ferraris
- Brain Science Institute, Department of Neurology, and Department of
Molecular and Comparative
Pathobiology, Johns Hopkins University, Baltimore, Maryland 21205, United States
| | - Jesse Alt
- Brain Science Institute, Department of Neurology, and Department of
Molecular and Comparative
Pathobiology, Johns Hopkins University, Baltimore, Maryland 21205, United States
| | - Ajit G. Thomas
- Brain Science Institute, Department of Neurology, and Department of
Molecular and Comparative
Pathobiology, Johns Hopkins University, Baltimore, Maryland 21205, United States
| | - Rana Rais
- Brain Science Institute, Department of Neurology, and Department of
Molecular and Comparative
Pathobiology, Johns Hopkins University, Baltimore, Maryland 21205, United States
| | - Camilo Rojas
- Brain Science Institute, Department of Neurology, and Department of
Molecular and Comparative
Pathobiology, Johns Hopkins University, Baltimore, Maryland 21205, United States
| | - Ying Wu
- Brain Science Institute, Department of Neurology, and Department of
Molecular and Comparative
Pathobiology, Johns Hopkins University, Baltimore, Maryland 21205, United States
| | - Krystyna
M. Wozniak
- Brain Science Institute, Department of Neurology, and Department of
Molecular and Comparative
Pathobiology, Johns Hopkins University, Baltimore, Maryland 21205, United States
| | - Barbara S. Slusher
- Brain Science Institute, Department of Neurology, and Department of
Molecular and Comparative
Pathobiology, Johns Hopkins University, Baltimore, Maryland 21205, United States
| | - Takashi Tsukamoto
- Brain Science Institute, Department of Neurology, and Department of
Molecular and Comparative
Pathobiology, Johns Hopkins University, Baltimore, Maryland 21205, United States
| |
Collapse
|
24
|
Katane M, Yamada S, Kawaguchi G, Chinen M, Matsumura M, Ando T, Doi I, Nakayama K, Kaneko Y, Matsuda S, Saitoh Y, Miyamoto T, Sekine M, Yamaotsu N, Hirono S, Homma H. Identification of Novel D-Aspartate Oxidase Inhibitors by in Silico Screening and Their Functional and Structural Characterization in Vitro. J Med Chem 2015; 58:7328-40. [PMID: 26322531 DOI: 10.1021/acs.jmedchem.5b00871] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
D-Aspartate oxidase (DDO) is a degradative enzyme that is stereospecific for acidic D-amino acids, including D-aspartate, a potential agonist of the N-methyl-D-aspartate (NMDA) receptor. Dysfunction of NMDA receptor-mediated neurotransmission has been implicated in the onset of various mental disorders, such as schizophrenia. Hence, a DDO inhibitor that increases the brain levels of D-aspartate and thereby activates NMDA receptor function is expected to be a useful compound. To search for potent DDO inhibitor(s), a large number of compounds were screened in silico, and several compounds were identified as candidates. They were then characterized and evaluated as novel DDO inhibitors in vitro (e.g., the inhibitor constant value of 5-aminonicotinic acid for human DDO was 3.80 μM). The present results indicate that some of these compounds may serve as lead compounds for the development of a clinically useful DDO inhibitor and as active site probes to elucidate the structure-function relationships of DDO.
Collapse
Affiliation(s)
- Masumi Katane
- Laboratory of Biomolecular Science, Graduate School of Pharmaceutical and Life Sciences, Kitasato University , 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Shota Yamada
- Laboratory of Biomolecular Science, Graduate School of Pharmaceutical and Life Sciences, Kitasato University , 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Go Kawaguchi
- Laboratory of Biomolecular Science, Graduate School of Pharmaceutical and Life Sciences, Kitasato University , 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Mana Chinen
- Laboratory of Biomolecular Science, Graduate School of Pharmaceutical and Life Sciences, Kitasato University , 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Maya Matsumura
- Laboratory of Biomolecular Science, Graduate School of Pharmaceutical and Life Sciences, Kitasato University , 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Takemi Ando
- Laboratory of Biomolecular Science, Graduate School of Pharmaceutical and Life Sciences, Kitasato University , 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Issei Doi
- Laboratory of Physical Chemistry for Drug Design, Graduate School of Pharmaceutical and Life Sciences, Kitasato University , 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Kazuki Nakayama
- Laboratory of Biomolecular Science, Graduate School of Pharmaceutical and Life Sciences, Kitasato University , 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Yuusuke Kaneko
- Laboratory of Biomolecular Science, Graduate School of Pharmaceutical and Life Sciences, Kitasato University , 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Satsuki Matsuda
- Laboratory of Biomolecular Science, Graduate School of Pharmaceutical and Life Sciences, Kitasato University , 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Yasuaki Saitoh
- Laboratory of Biomolecular Science, Graduate School of Pharmaceutical and Life Sciences, Kitasato University , 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Tetsuya Miyamoto
- Laboratory of Biomolecular Science, Graduate School of Pharmaceutical and Life Sciences, Kitasato University , 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Masae Sekine
- Laboratory of Biomolecular Science, Graduate School of Pharmaceutical and Life Sciences, Kitasato University , 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Noriyuki Yamaotsu
- Laboratory of Physical Chemistry for Drug Design, Graduate School of Pharmaceutical and Life Sciences, Kitasato University , 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Shuichi Hirono
- Laboratory of Physical Chemistry for Drug Design, Graduate School of Pharmaceutical and Life Sciences, Kitasato University , 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Hiroshi Homma
- Laboratory of Biomolecular Science, Graduate School of Pharmaceutical and Life Sciences, Kitasato University , 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| |
Collapse
|
25
|
Terry-Lorenzo RT, Masuda K, Sugao K, Fang QK, Orsini MA, Sacchi S, Pollegioni L. High-Throughput Screening Strategy Identifies Allosteric, Covalent Human D-Amino Acid Oxidase Inhibitor. ACTA ACUST UNITED AC 2015; 20:1218-31. [DOI: 10.1177/1087057115600413] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2015] [Accepted: 07/21/2015] [Indexed: 01/14/2023]
Abstract
Genome-wide association studies have linked polymorphisms in the gene G72 to schizophrenia risk in several human populations. Although controversial, biochemical experiments have suggested that the mechanistic link of G72 to schizophrenia is due to the G72 protein product, pLG72, exerting a regulatory effect on human D-amino acid oxidase (hDAAO) activity. In an effort to identify hDAAO inhibitors of novel mechanism of action, we designed a pLG72-directed hDAAO activity assay suitable for high-throughput screening (HTS). During assay development, we confirmed that pLG72 was an inhibitor of hDAAO. Thus, our assay employed an IC20 pLG72 concentration that was high enough to allow dynamic pLG72-hDAAO complexes to form but with sufficient remaining hDAAO activity to measure during an HTS. After conducting an approximately 150,000-compound HTS, we further characterized a class of compound hits that were less potent hDAAO inhibitors when pLG72 was present. Focusing primarily on compound 2 [2-(2,5-dimethylphenyl)-6-fluorobenzo[d]isothiazol-3(2H)-on], we demonstrated that these compounds inhibited hDAAO via an allosteric, covalent mechanism. Although there is significant interest in the therapeutic potential of compound 2 and its analogues, their sensitivity to reducing agents and their capacity to bind cysteines covalently would need to be addressed during therapeutic drug development.
Collapse
Affiliation(s)
- Ryan T. Terry-Lorenzo
- Discovery and Preclinical Research Department, Sunovion Pharmaceuticals, Marlborough, MA, USA
| | - Keiki Masuda
- Genomic Science Laboratories, Sumitomo Dainippon Pharma (DSP), Osaka, Japan
| | - Kohtaroh Sugao
- Genomic Science Laboratories, Sumitomo Dainippon Pharma (DSP), Osaka, Japan
| | - Q. Kevin Fang
- Discovery and Preclinical Research Department, Sunovion Pharmaceuticals, Marlborough, MA, USA
| | - Michael A. Orsini
- Discovery and Preclinical Research Department, Sunovion Pharmaceuticals, Marlborough, MA, USA
| | - Silvia Sacchi
- Dipartimento di Biotecnologie e Scienze della Vita, Università degli Studi dell’Insubria, Varese, Italy, and The Protein Factory, Politecnico di Milano and Università degli Studi dell’Insubria, Milano, Italy
| | - Loredano Pollegioni
- Dipartimento di Biotecnologie e Scienze della Vita, Università degli Studi dell’Insubria, Varese, Italy, and The Protein Factory, Politecnico di Milano and Università degli Studi dell’Insubria, Milano, Italy
| |
Collapse
|
26
|
Llona-Minguez S, Desroses M, Ghassemian A, Jacques SA, Eriksson L, Isacksson R, Koolmeister T, Stenmark P, Scobie M, Helleday T. Vinylic MIDA Boronates: New Building Blocks for the Synthesis of Aza-Heterocycles. Chemistry 2015; 21:7394-8. [PMID: 25809883 DOI: 10.1002/chem.201406549] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2014] [Indexed: 01/23/2023]
Abstract
A two-step synthesis of structurally diverse pyrrole-containing bicyclic systems is reported. ortho-Nitro-haloarenes coupled with vinylic N-methyliminodiacetic acid (MIDA) boronates generate ortho-vinyl-nitroarenes, which undergo a "metal-free" nitrene insertion, resulting in a new pyrrole ring. This novel synthetic approach has a wide substrate tolerance and it is applicable in the preparation of more complex "drug-like" molecules. Interestingly, an ortho-nitro-allylarene derivative furnished a cyclic β-aminophosphonate motif.
Collapse
Affiliation(s)
- Sabin Llona-Minguez
- Science for Life Laboratory, Division of Translational, Medicine & Chemical Biology, Department of Medical Biochemistry & Biophysics, Karolinska Institutet, Stockholm, 171 21 (Sweden) http://www.helleday.org.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Zimmermann SC, Rais R, Alt J, Burzynski C, Slusher BS, Tsukamoto T. Structure-Metabolism Relationships in the Glucuronidation of d-Amino Acid Oxidase Inhibitors. ACS Med Chem Lett 2014; 5:1251-3. [PMID: 25408840 DOI: 10.1021/ml500335z] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2014] [Accepted: 10/21/2014] [Indexed: 11/30/2022] Open
Abstract
Representative d-amino acid oxidase (DAAO) inhibitors were subjected to in vitro liver microsomal stability tests in the absence or presence of uridine diphosphate glucuronic acid (UDPGA). While carboxylate-based DAAO inhibitors displayed little glucuronidation, most DAAO inhibitors containing α-hydroxycarbonyl moiety exhibited nearly complete glucuronidation within 30 min. The one exception was 6-[2-(3,5-difluorophenyl)ethyl]-4-hydroxypyridazin-3(2H)-one 10, which exhibited some degree of resistance to glucuronidation by liver microsomes from mice, rats, and humans.
Collapse
Affiliation(s)
- Sarah C. Zimmermann
- Department of Neurology and Brain Science
Institute, Johns Hopkins University, Baltimore, Maryland 21205, United States
| | - Rana Rais
- Department of Neurology and Brain Science
Institute, Johns Hopkins University, Baltimore, Maryland 21205, United States
| | - Jesse Alt
- Department of Neurology and Brain Science
Institute, Johns Hopkins University, Baltimore, Maryland 21205, United States
| | - Caitlin Burzynski
- Medicinal Chemistry Section, Molecular Targets and Medications Discovery
Branch, National Institute on Drug Abuse—Intramural Research Program, Baltimore, Maryland 21224, United States
| | - Barbara S. Slusher
- Department of Neurology and Brain Science
Institute, Johns Hopkins University, Baltimore, Maryland 21205, United States
| | - Takashi Tsukamoto
- Department of Neurology and Brain Science
Institute, Johns Hopkins University, Baltimore, Maryland 21205, United States
| |
Collapse
|
28
|
Novel human D-amino acid oxidase inhibitors stabilize an active-site lid-open conformation. Biosci Rep 2014; 34:BSR20140071. [PMID: 25001371 PMCID: PMC4127593 DOI: 10.1042/bsr20140071] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
The NMDAR (N-methyl-D-aspartate receptor) is a central regulator of synaptic plasticity and learning and memory. hDAAO (human D-amino acid oxidase) indirectly reduces NMDAR activity by degrading the NMDAR co-agonist D-serine. Since NMDAR hypofunction is thought to be a foundational defect in schizophrenia, hDAAO inhibitors have potential as treatments for schizophrenia and other nervous system disorders. Here, we sought to identify novel chemicals that inhibit hDAAO activity. We used computational tools to design a focused, purchasable library of compounds. After screening this library for hDAAO inhibition, we identified the structurally novel compound, 'compound 2' [3-(7-hydroxy-2-oxo-4-phenyl-2H-chromen-6-yl)propanoic acid], which displayed low nM hDAAO inhibitory potency (Ki=7 nM). Although the library was expected to enrich for compounds that were competitive for both D-serine and FAD, compound 2 actually was FAD uncompetitive, much like canonical hDAAO inhibitors such as benzoic acid. Compound 2 and an analog were independently co-crystalized with hDAAO. These compounds stabilized a novel conformation of hDAAO in which the active-site lid was in an open position. These results confirm previous hypotheses regarding active-site lid flexibility of mammalian D-amino acid oxidases and could assist in the design of the next generation of hDAAO inhibitors.
Collapse
|
29
|
Vijay Kumar S, Saraiah B, Parameshwarappa G, Ila H, Verma GK. Synthesis of N-Functionalized/NH-Multisubstituted Indoles, Thienopyrroles, Pyrroloindoles, and Pyrazolopyrroles via Sequential One-Pot Base-Mediated and Copper-Catalyzed Inter- and Intramolecular Amination of 2-[2-Bromo(het)aryl]-3-(het)aryl-3-(methylthio)acrylonitriles. J Org Chem 2014; 79:7961-78. [DOI: 10.1021/jo501114a] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Affiliation(s)
- S. Vijay Kumar
- New
Chemistry Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560064, India
| | - B. Saraiah
- New
Chemistry Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560064, India
| | - G. Parameshwarappa
- New
Chemistry Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560064, India
| | - H. Ila
- New
Chemistry Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur, Bangalore 560064, India
| | - Girijesh K. Verma
- Department
of Chemistry, Banaras Hindu University, Varanasi 221005, India
| |
Collapse
|
30
|
Xie D, Wang Y, Xie J, Lu J, Cui J, Zhang M, Fu L, Wang Y. Quinoxaline-2,3-diones: potential d-amino acid oxidase (DAAO) inhibitors. Med Chem Res 2014. [DOI: 10.1007/s00044-014-1068-z] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
|
31
|
Wichapong K, Nueangaudom A, Pianwanit S, Tanaka F, Kokpol S. Molecular dynamics simulation, binding free energy calculation and molecular docking of human D-amino acid oxidase (DAAO) with its inhibitors. MOLECULAR SIMULATION 2014. [DOI: 10.1080/08927022.2013.854892] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
32
|
Zhao H, Koenig SG, Dankwardt JW, Singh SP. Practical Nonazide Synthesis of a d-Amino Acid Oxidase Inhibitor via a Sequential Erlenmeyer–Plöchl Reaction and Ligand-Free Copper(I) Amination Protocol. Org Process Res Dev 2013. [DOI: 10.1021/op4001737] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Hang Zhao
- Chemical Process Research and Development, Sunovion Pharmaceuticals Inc., 84 Waterford
Drive, Marlborough, Massachusetts 01752, United States
| | - Stefan G. Koenig
- Chemical Process Research and Development, Sunovion Pharmaceuticals Inc., 84 Waterford
Drive, Marlborough, Massachusetts 01752, United States
| | - John W. Dankwardt
- Chemical Process Research and Development, Sunovion Pharmaceuticals Inc., 84 Waterford
Drive, Marlborough, Massachusetts 01752, United States
| | - Surendra P. Singh
- Chemical Process Research and Development, Sunovion Pharmaceuticals Inc., 84 Waterford
Drive, Marlborough, Massachusetts 01752, United States
| |
Collapse
|
33
|
D-Serine metabolism: new insights into the modulation of D-amino acid oxidase activity. Biochem Soc Trans 2013; 41:1551-6. [DOI: 10.1042/bst20130184] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Over the years, accumulating evidence has indicated that D-serine represents the main endogenous ligand of NMDA (N-methyl-D-aspartate) receptors. In the brain, the concentration of D-serine stored in cells is defined by the activity of two enzymes: serine racemase (responsible for both the synthesis and degradation) and D-amino acid oxidase (which catalyses D-serine degradation). The present review is focused on human D-amino acid oxidase, discussing the mechanisms involved in modulating enzyme activity and stability, with the aim to substantiate the pivotal role of D-amino acid oxidase in brain D-serine metabolism.
Collapse
|
34
|
Hopkins SC, Campbell UC, Heffernan MLR, Spear KL, Jeggo RD, Spanswick DC, Varney MA, Large TH. Effects of D-amino acid oxidase inhibition on memory performance and long-term potentiation in vivo. Pharmacol Res Perspect 2013; 1:e00007. [PMID: 25505561 PMCID: PMC4184572 DOI: 10.1002/prp2.7] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2013] [Accepted: 08/16/2013] [Indexed: 12/11/2022] Open
Abstract
N-methyl-d-aspartate receptor (NMDAR) activation can initiate changes in synaptic strength, evident as long-term potentiation (LTP), and is a key molecular correlate of memory formation. Inhibition of d-amino acid oxidase (DAAO) may increase NMDAR activity by regulating d-serine concentrations, but which neuronal and behavioral effects are influenced by DAAO inhibition remain elusive. In anesthetized rats, extracellular field excitatory postsynaptic potentials (fEPSPs) were recorded before and after a theta frequency burst stimulation (TBS) of the Schaffer collateral pathway of the CA1 region in the hippocampus. Memory performance was assessed after training with tests of contextual fear conditioning (FC, mice) and novel object recognition (NOR, rats). Oral administration of 3, 10, and 30 mg/kg 4H-furo[3,2-b]pyrrole-5-carboxylic acid (SUN) produced dose-related and steady increases of cerebellum d-serine in rats and mice, indicative of lasting inhibition of central DAAO. SUN administered 2 h prior to training improved contextual fear conditioning in mice and novel object recognition memory in rats when tested 24 h after training. In anesthetized rats, LTP was established proportional to the number of TBS trains. d-cycloserine (DCS) was used to identify a submaximal level of LTP (5× TBS) that responded to NMDA receptor activation; SUN administered at 10 mg/kg 3-4 h prior to testing similarly increased in vivo LTP levels compared to vehicle control animals. Interestingly, in vivo administration of DCS also increased brain d-serine concentrations. These results indicate that DAAO inhibition increased NMDAR-related synaptic plasticity during phases of post training memory consolidation to improve memory performance in hippocampal-dependent behavioral tests.
Collapse
Affiliation(s)
| | | | | | - Kerry L Spear
- Sunovion Pharmaceuticals IncMarlborough, Massachusetts
| | | | - David C Spanswick
- Neurosolutions Ltd.Coventry, U.K
- Department of Physiology, Monash UniversityClayton, Victoria, Australia
- Warwick Medical School, University of WarwickCoventry, U.K
| | - Mark A Varney
- Sunovion Pharmaceuticals IncMarlborough, Massachusetts
| | | |
Collapse
|
35
|
Katane M, Matsuda S, Saitoh Y, Sekine M, Furuchi T, Koyama N, Nakagome I, Tomoda H, Hirono S, Homma H. The Antiviral Drug Acyclovir Is a Slow-Binding Inhibitor of d-Amino Acid Oxidase. Biochemistry 2013; 52:5665-74. [DOI: 10.1021/bi400478a] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Affiliation(s)
- Masumi Katane
- Laboratory of Biomolecular Science,
Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641,
Japan
| | - Satsuki Matsuda
- Laboratory of Biomolecular Science,
Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641,
Japan
| | - Yasuaki Saitoh
- Laboratory of Biomolecular Science,
Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641,
Japan
| | - Masae Sekine
- Laboratory of Biomolecular Science,
Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641,
Japan
| | - Takemitsu Furuchi
- Laboratory of Biomolecular Science,
Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641,
Japan
| | - Nobuhiro Koyama
- Laboratory of Microbial
Chemistry,
Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641,
Japan
| | - Izumi Nakagome
- Laboratory of Physical
Chemistry
for Drug Design, Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo
108-8641, Japan
| | - Hiroshi Tomoda
- Laboratory of Microbial
Chemistry,
Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641,
Japan
| | - Shuichi Hirono
- Laboratory of Physical
Chemistry
for Drug Design, Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo
108-8641, Japan
| | - Hiroshi Homma
- Laboratory of Biomolecular Science,
Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641,
Japan
| |
Collapse
|
36
|
Raje M, Hin N, Duvall B, Ferraris DV, Berry JF, Thomas AG, Alt J, Rojas C, Slusher BS, Tsukamoto T. Synthesis of kojic acid derivatives as secondary binding site probes of D-amino acid oxidase. Bioorg Med Chem Lett 2013; 23:3910-3. [PMID: 23683589 PMCID: PMC3678123 DOI: 10.1016/j.bmcl.2013.04.062] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2013] [Revised: 04/17/2013] [Accepted: 04/22/2013] [Indexed: 10/26/2022]
Abstract
A series of kojic acid (5-hydroxy-2-hydroxymethyl-4H-pyran-4-one) derivatives were synthesized and tested for their ability to inhibit D-amino acid oxidase (DAAO). Various substituents were incorporated into kojic acid at its 2-hydroxymethyl group. These analogs serve as useful molecular probes to explore the secondary binding site, which can be exploited in designing more potent DAAO inhibitors.
Collapse
Affiliation(s)
- Mithun Raje
- Department of Neurology, Johns Hopkins University, Baltimore, MD 21205, USA
| | - Niyada Hin
- Brain Science Institute, Johns Hopkins University, Baltimore, MD 21205, USA
| | - Bridget Duvall
- Brain Science Institute, Johns Hopkins University, Baltimore, MD 21205, USA
| | - Dana V. Ferraris
- Brain Science Institute, Johns Hopkins University, Baltimore, MD 21205, USA
| | - James F. Berry
- Department of Neurology, Johns Hopkins University, Baltimore, MD 21205, USA
| | - Ajit G. Thomas
- Brain Science Institute, Johns Hopkins University, Baltimore, MD 21205, USA
| | - Jesse Alt
- Brain Science Institute, Johns Hopkins University, Baltimore, MD 21205, USA
| | - Camilo Rojas
- Brain Science Institute, Johns Hopkins University, Baltimore, MD 21205, USA
| | - Barbara S. Slusher
- Department of Neurology, Johns Hopkins University, Baltimore, MD 21205, USA
- Brain Science Institute, Johns Hopkins University, Baltimore, MD 21205, USA
| | - Takashi Tsukamoto
- Department of Neurology, Johns Hopkins University, Baltimore, MD 21205, USA
- Brain Science Institute, Johns Hopkins University, Baltimore, MD 21205, USA
| |
Collapse
|
37
|
Hopkins SC, Heffernan MLR, Saraswat LD, Bowen CA, Melnick L, Hardy LW, Orsini MA, Allen MS, Koch P, Spear KL, Foglesong RJ, Soukri M, Chytil M, Fang QK, Jones SW, Varney MA, Panatier A, Oliet SHR, Pollegioni L, Piubelli L, Molla G, Nardini M, Large TH. Structural, Kinetic, and Pharmacodynamic Mechanisms of d-Amino Acid Oxidase Inhibition by Small Molecules. J Med Chem 2013; 56:3710-24. [DOI: 10.1021/jm4002583] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Seth C. Hopkins
- Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts 01752, United States
| | | | - Lakshmi D. Saraswat
- Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts 01752, United States
| | - Carrie A. Bowen
- Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts 01752, United States
| | - Laurence Melnick
- Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts 01752, United States
| | - Larry W. Hardy
- Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts 01752, United States
| | - Michael A. Orsini
- Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts 01752, United States
| | | | - Patrick Koch
- Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts 01752, United States
| | - Kerry L. Spear
- Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts 01752, United States
| | | | | | - Milan Chytil
- Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts 01752, United States
| | - Q. Kevin Fang
- Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts 01752, United States
| | - Steven W. Jones
- Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts 01752, United States
| | - Mark A. Varney
- Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts 01752, United States
| | - Aude Panatier
- Neurocentre Magendie, Inserm U862 and Université de Bordeaux, Bordeaux, F-33077, France
| | - Stephane H. R. Oliet
- Neurocentre Magendie, Inserm U862 and Université de Bordeaux, Bordeaux, F-33077, France
| | - Loredano Pollegioni
- Dipartimento di Biotecnologie
e Scienze della Vita, Università degli Studi dell’Insubria, Via J. H. Dunant 3, 21100 Varese, Italy
- The Protein Factory, Politecnico di Milano, ICRM-CNR and Università degli Studi dell’Insubria, Via Mancinelli 7,
20131 Milano, Italy
| | - Luciano Piubelli
- Dipartimento di Biotecnologie
e Scienze della Vita, Università degli Studi dell’Insubria, Via J. H. Dunant 3, 21100 Varese, Italy
- The Protein Factory, Politecnico di Milano, ICRM-CNR and Università degli Studi dell’Insubria, Via Mancinelli 7,
20131 Milano, Italy
| | - Gianluca Molla
- Dipartimento di Biotecnologie
e Scienze della Vita, Università degli Studi dell’Insubria, Via J. H. Dunant 3, 21100 Varese, Italy
- The Protein Factory, Politecnico di Milano, ICRM-CNR and Università degli Studi dell’Insubria, Via Mancinelli 7,
20131 Milano, Italy
| | - Marco Nardini
- Department of Biosciences, University of Milan, I-20133 Milano, Italy
| | - Thomas H. Large
- Sunovion Pharmaceuticals Inc., Marlborough, Massachusetts 01752, United States
| |
Collapse
|
38
|
Hopkins SC, Zhao FY, Bowen CA, Fang X, Wei H, Heffernan MLR, Spear KL, Spanswick DC, Varney MA, Large TH. Pharmacodynamic Effects of a d-Amino Acid Oxidase Inhibitor Indicate a Spinal Site of Action in Rat Models of Neuropathic Pain. J Pharmacol Exp Ther 2013; 345:502-11. [DOI: 10.1124/jpet.113.204016] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
39
|
Katane M, Osaka N, Matsuda S, Maeda K, Kawata T, Saitoh Y, Sekine M, Furuchi T, Doi I, Hirono S, Homma H. Identification of Novel d-Amino Acid Oxidase Inhibitors by in Silico Screening and Their Functional Characterization in Vitro. J Med Chem 2013; 56:1894-907. [DOI: 10.1021/jm3017865] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Masumi Katane
- Laboratory of Biomolecular Science,
Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1
Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Naoko Osaka
- Laboratory of Biomolecular Science,
Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1
Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Satsuki Matsuda
- Laboratory of Biomolecular Science,
Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1
Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Kazuhiro Maeda
- Laboratory of Biomolecular Science,
Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1
Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Tomonori Kawata
- Laboratory of Biomolecular Science,
Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1
Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Yasuaki Saitoh
- Laboratory of Biomolecular Science,
Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1
Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Masae Sekine
- Laboratory of Biomolecular Science,
Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1
Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Takemitsu Furuchi
- Laboratory of Biomolecular Science,
Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1
Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Issei Doi
- Laboratory of Physical Chemistry
for Drug Design, Graduate School of Pharmaceutical Sciences, Kitasato
University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
- First Research Department, Toyama
Chemical Co., Ltd., 2-4-1 Shimookui, Toyama, Toyama 930-8508, Japan
| | - Shuichi Hirono
- Laboratory of Physical Chemistry
for Drug Design, Graduate School of Pharmaceutical Sciences, Kitasato
University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
| | - Hiroshi Homma
- Laboratory of Biomolecular Science,
Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1
Shirokane, Minato-ku, Tokyo 108-8641, Japan
| |
Collapse
|
40
|
Nunes EA, MacKenzie EM, Rossolatos D, Perez-Parada J, Baker GB, Dursun SM. D-serine and schizophrenia: an update. Expert Rev Neurother 2012; 12:801-12. [PMID: 22853788 DOI: 10.1586/ern.12.65] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Considering the lengthy history of pharmacological treatment of schizophrenia, the development of novel antipsychotic agents targeting the glutamatergic system is relatively new. A glutamatergic deficit has been proposed to underlie many of the symptoms typically observed in schizophrenia, particularly the negative and cognitive symptoms (which are less likely to respond to current treatments). D-serine is an important coagonist of the glutamate NMDA receptor, and accumulating evidence suggests that D-serine levels and/or activity may be dysfunctional in schizophrenia and that facilitation of D-serine transmission could provide a significant therapeutic breakthrough, especially where conventional treatments have fallen short. A summary of the relevant animal data, as well as genetic studies and clinical trials examining D-serine as an adjunct to standard antipsychotic therapy, is provided in this article. Together, the evidence suggests that research on the next generation of antipsychotic agents should include studies on increasing brain levels of D-serine or mimicking its action on the NMDA receptor.
Collapse
Affiliation(s)
- Emerson A Nunes
- Neurochemical Research Unit, Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada
| | | | | | | | | | | |
Collapse
|
41
|
Morrow JA, Gilfillan R, Neale SA. Glutamatergic Approaches for the Treatment of Schizophrenia. DRUG DISCOVERY FOR PSYCHIATRIC DISORDERS 2012. [DOI: 10.1039/9781849734943-00056] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system and plays a key role in most aspects of normal brain function including cognition, learning and memory. Dysfunction of glutamatergic neurotransmission has been implicated in a number of neurological and psychiatric disorders with a growing body of evidence suggesting that hypofunction of glutamatergic neurotransmission via the N-methyl-d-aspartate (NMDA) receptor plays an important role in the pathophysiology of schizophrenia. It thus follows that potentiation of NMDA receptor function via pharmacological manipulation may provide therapeutic utility for the treatment of schizophrenia and a number of different approaches are currently being pursued by the pharmaceutical industry with this aim in mind. These include strategies that target the glycine/d-serine site of the NMDA receptor (glycine transporter GlyT1, d-serine transporter ASC-1 and d-amino acid oxidase (DAAO) inhibitors) together with those aimed at enhancing glutamatergic neurotransmission via modulation of AMPA receptor and metabotropic glutamate receptor function. Such efforts are now beginning to bear fruit with compounds such as the GlyT1 inhibitor RG1678 and mGlu2 agonist LY2140023 proving to have clinical meaningful effects in phase II clinical trials. While more studies are required to confirm long-term efficacy, functional outcome and safety in schizophrenic agents, these agents hold real promise for addressing unmet medical needs, in particular refractory negative and cognitive symptoms, not currently addressed by existing antipsychotic agents.
Collapse
Affiliation(s)
- John A. Morrow
- Neuroscience and Ophthalmology, Merck Research Laboratories 2015 Galloping Hill Road, Kenilworth, New Jersey 07033 USA
| | - Robert Gilfillan
- Discovery Chemistry, Merck Research Laboratories 770 Sumneytown Pike, West Point, Pennsylvania 19486 USA
| | - Stuart A. Neale
- Neurexpert Ltd Ground Floor, 2 Woodberry Grove, North Finchley, London, N12 0DR UK
| |
Collapse
|
42
|
Berry JF, Ferraris DV, Duvall B, Hin N, Rais R, Alt J, Thomas AG, Rojas C, Hashimoto K, Slusher BS, Tsukamoto T. Synthesis and SAR of 1-hydroxy-1H-benzo[d]imidazol-2(3H)-ones as Inhibitors of D-Amino Acid Oxidase. ACS Med Chem Lett 2012; 3:839-843. [PMID: 23243487 DOI: 10.1021/ml300212a] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
A series of 1-hydroxy-1H-benzo[d]imidazol-2(3H)-ones were synthesized and evaluated for their ability to inhibit human and porcine forms of D-amino acid oxidase (DAAO). Inhibitory potency is largely dependent on the size and position of substituents on the benzene ring with IC(50) values of the compounds ranging from 70 nM to greater than 100 µM. Structure-activity relationships of this new class of DAAO inhibitors will be presented in detail along with comparisons to previously published SAR data from other classes of DAAO inhibitors. Some of these compounds were given to mice orally together with D-serine to assess their effects on plasma D-serine pharmacokinetics.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - Kenji Hashimoto
- Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health,
1-8-1 Inohana, Chiba 260-8670, Japan
| | | | | |
Collapse
|
43
|
Structure–function relationships in human d-amino acid oxidase. Amino Acids 2012; 43:1833-50. [DOI: 10.1007/s00726-012-1345-4] [Citation(s) in RCA: 77] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2012] [Accepted: 06/16/2012] [Indexed: 01/01/2023]
|
44
|
Straightforward copper-catalyzed synthesis of pyrrolopyrazoles from halogenated pyrazolecarbaldehydes. Tetrahedron Lett 2012. [DOI: 10.1016/j.tetlet.2012.05.148] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
45
|
Iwasa S, Tabara H, Song Z, Nakabayashi M, Yokoyama Y, Fukushima T. Inhibition of D-amino acid oxidase activity by antipsychotic drugs evaluated by a fluorometric assay using D-kynurenine as substrate. YAKUGAKU ZASSHI 2012; 131:1111-6. [PMID: 21720142 DOI: 10.1248/yakushi.131.1111] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A facile fluorometric assay using D-kynurenine as a substrate was utilized for evaluating the inhibition of D-amino acid oxidase (DAAO), which is one of the products of a susceptibility gene for schizophrenia, by commercial antipsychotic drugs, namely, chlorpromazine (CPZ), carbamazepine, sulpiride, quetiapine, and imipramine. CPZ inhibited DAAO (65.8 ± 13.2 μM, n = 3) as reported previously, and other drugs also inhibited DAAO activity. Among these, quetiapine had the smallest IC(50) value (19.5 ± 2.60 μM, n = 3). The proposed assay can be useful for the evaluation or screening of DAAO-inhibitory drugs.
Collapse
Affiliation(s)
- Sumiko Iwasa
- Department of Analytical Chemistry, Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan
| | | | | | | | | | | |
Collapse
|
46
|
Frattini LF, Piubelli L, Sacchi S, Molla G, Pollegioni L. Is rat an appropriate animal model to study the involvement of D-serine catabolism in schizophrenia? Insights from characterization of D-amino acid oxidase. FEBS J 2011; 278:4362-73. [PMID: 21981077 DOI: 10.1111/j.1742-4658.2011.08354.x] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
D-Amino acid oxidase (DAAO; EC1.4.3.3) has been proposed to play a main role in the degradation of D-serine, an allosteric activator of the N-methyl-D-aspartate-type glutamate receptor in the human brain, and to be associated with the onset of schizophrenia. To prevent excessive D-serine degradation, novel drugs for schizophrenia treatment based on DAAO inhibition were designed and tested on rats. However, the properties of rat DAAO are unknown and various in vivo trials have demonstrated the effects of DAAO inhibitors on d-serine concentration in rats. In the present study, rat DAAO was efficiently expressed in Escherichia coli. The recombinant enzyme was purified as an active, 40 kDa monomeric flavoenzyme showing the basic properties of the dehydrogenase-oxidase class of flavoproteins. Rat DAAO differs significantly from the human counterpart because: (a) it possesses a different substrate specificity; (b) it shows a lower kinetic efficiency, mainly as a result of a low substrate affinity; (c) it differs in affinity for the binding of classical inhibitors; (d) it is a stable monomer in the absence of an active site ligand; and (e) it interacts with the mammalian protein modulator pLG72 yielding a ~100 kDa complex in addition to the ~200 kDa one, as formed by the human DAAO. Furthermore, the concentration of endogenous D-serine in U87 glioblastoma cells was not affected by transfection with rat DAAO, whereas it was significantly decreased when expressing the human homologue. These results raise doubt on the use of the rat as a model system for testing new drugs against schizophrenia and indicate a different physiological function of DAAO in rodents and humans.
Collapse
Affiliation(s)
- Luca F Frattini
- Dipartimento di Biotecnologie e Scienze della Vita, Università degli studi dell'Insubria, Varese, Italy
| | | | | | | | | |
Collapse
|
47
|
Strick CA, Li C, Scott L, Harvey B, Hajós M, Steyn SJ, Piotrowski MA, James LC, Downs JT, Rago B, Becker SL, El-Kattan A, Xu Y, Ganong AH, Tingley FD, Ramirez AD, Seymour PA, Guanowsky V, Majchrzak MJ, Fox CB, Schmidt CJ, Duplantier AJ. Modulation of NMDA receptor function by inhibition of D-amino acid oxidase in rodent brain. Neuropharmacology 2011; 61:1001-15. [PMID: 21763704 DOI: 10.1016/j.neuropharm.2011.06.029] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2011] [Revised: 06/28/2011] [Accepted: 06/29/2011] [Indexed: 01/16/2023]
Abstract
Observations that N-Methyl-D-Aspartate (NMDA) antagonists produce symptoms in humans that are similar to those seen in schizophrenia have led to the current hypothesis that schizophrenia might result from NMDA receptor hypofunction. Inhibition of D-amino acid oxidase (DAAO), the enzyme responsible for degradation of D-serine, should lead to increased levels of this co-agonist at the NMDA receptor, and thereby provide a therapeutic approach to schizophrenia. We have profiled some of the preclinical biochemical, electrophysiological, and behavioral consequences of administering potent and selective inhibitors of DAAO to rodents to begin to test this hypothesis. Inhibition of DAAO activity resulted in a significant dose and time dependent increase in D-serine only in the cerebellum, although a time delay was observed between peak plasma or brain drug concentration and cerebellum D-serine response. Pharmacokinetic/pharmacodynamic (PK/PD) modeling employing a mechanism-based indirect response model was used to characterize the correlation between free brain drug concentration and D-serine accumulation. DAAO inhibitors had little or no activity in rodent models considered predictive for antipsychotic activity. The inhibitors did, however, affect cortical activity in the Mescaline-Induced Scratching model, produced a modest but significant increase in NMDA receptor-mediated synaptic currents in primary neuronal cultures from rat hippocampus, and resulted in a significant increase in evoked hippocampal theta rhythm, an in vivo electrophysiological model of hippocampal activity. These findings demonstrate that although DAAO inhibition did not cause a measurable increase in D-serine in forebrain, it did affect hippocampal and cortical activity, possibly through augmentation of NMDA receptor-mediated currents.
Collapse
MESH Headings
- Animals
- Brain/drug effects
- Brain/metabolism
- Central Nervous System Stimulants/metabolism
- Central Nervous System Stimulants/pharmacology
- Cyclic GMP/analysis
- Cyclic GMP/biosynthesis
- D-Amino-Acid Oxidase/antagonists & inhibitors
- D-Amino-Acid Oxidase/metabolism
- D-Amino-Acid Oxidase/physiology
- Drug Evaluation, Preclinical
- Electroencephalography
- Habituation, Psychophysiologic/drug effects
- Habituation, Psychophysiologic/physiology
- Harmaline/metabolism
- Hippocampus/drug effects
- Hippocampus/metabolism
- Male
- Maze Learning/drug effects
- Maze Learning/physiology
- Memory, Short-Term/drug effects
- Memory, Short-Term/physiology
- Mescaline/pharmacology
- Mice
- Miniature Postsynaptic Potentials/drug effects
- Miniature Postsynaptic Potentials/physiology
- Models, Biological
- Models, Chemical
- Molecular Targeted Therapy
- Motor Activity/drug effects
- Motor Activity/physiology
- Pruritus/chemically induced
- Pruritus/prevention & control
- Psychomotor Agitation/drug therapy
- Rats
- Rats, Long-Evans
- Rats, Sprague-Dawley
- Receptors, N-Methyl-D-Aspartate/drug effects
- Receptors, N-Methyl-D-Aspartate/metabolism
- Sensory Gating/drug effects
- Sensory Gating/physiology
- Serine/blood
- Serotonin Receptor Agonists/pharmacology
Collapse
|
48
|
Biophysical and physicochemical methods differentiate highly ligand-efficient human D-amino acid oxidase inhibitors. Eur J Med Chem 2011; 46:4808-19. [PMID: 21880399 DOI: 10.1016/j.ejmech.2011.04.023] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2011] [Revised: 04/05/2011] [Accepted: 04/07/2011] [Indexed: 12/16/2022]
Abstract
Many early drug research efforts are too reductionist thereby not delivering key parameters such as kinetics and thermodynamics of target-ligand binding. A set of human D-Amino Acid Oxidase (DAAO) inhibitors 1-6 was applied to demonstrate the impact of key biophysical techniques and physicochemical methods in the differentiation of chemical entities that cannot be adequately distinguished on the basis of their normalized potency (ligand efficiency) values. The resulting biophysical and physicochemical data were related to relevant pharmacodynamic and pharmacokinetic properties. Surface Plasmon Resonance data indicated prolonged target-ligand residence times for 5 and 6 as compared to 1-4, based on the observed k(off) values. The Isothermal Titration Calorimetry-derived thermodynamic binding profiles of 1-6 to the DAAO enzyme revealed favorable contributions of both ΔH and ΔS to their ΔG values. Surprisingly, the thermodynamic binding profile of 3 elicited a substantially higher favorable contribution of ΔH to ΔG in comparison with the structurally closely related fused bicyclic acid 4. Molecular dynamics simulations and free energy calculations of 1, 3, and 4 led to novel insights into the thermodynamic properties of the binding process at an atomic level and in the different thermodynamic signatures of 3 and 4. The presented holistic approach is anticipated to facilitate the identification of compounds with best-in-class properties at an early research stage.
Collapse
|
49
|
O'Brien AG, Lévesque F, Seeberger PH. Continuous flow thermolysis of azidoacrylates for the synthesis of heterocycles and pharmaceutical intermediates. Chem Commun (Camb) 2011; 47:2688-90. [DOI: 10.1039/c0cc04481d] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
50
|
Caldinelli L, Molla G, Bracci L, Lelli B, Pileri S, Cappelletti P, Sacchi S, Pollegioni L. Effect of ligand binding on human D-amino acid oxidase: implications for the development of new drugs for schizophrenia treatment. Protein Sci 2010; 19:1500-12. [PMID: 20521334 DOI: 10.1002/pro.429] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
In human brain the flavoprotein D-amino acid oxidase (hDAAO) is responsible for the degradation of the neuromodulator D-serine, an important effector of NMDA-receptor mediated neurotransmission. Experimental evidence supports the concept that D-serine concentration increase by hDAAO inhibition may represent a valuable therapeutic approach to improve the symptoms in schizophrenia patients. This study investigated the effects on hDAAO conformation and stability of the substrate D-serine (or of the pseudo-substrate trifluoro-D-alanine), the FAD cofactor, and two inhibitors (benzoate, a classical substrate-competitive inhibitor and the drug chlorpromazine (CPZ), which competes with the cofactor). We demonstrated that all these compounds do not alter the interaction of hDAAO with its physiological partner pLG72. The ligands used affect the tertiary structure of hDAAO differently: benzoate or trifluoro-D-alanine binding increases the amount of the holoenzyme form in solution and stabilizes the flavoprotein, while CPZ binding favors a protein conformation resembling that of the apoprotein, which is more sensitive to degradation. Interestingly, the apoprotein form of hDAAO binds the substrate D-serine: this interaction increases FAD binding thus increasing the amount of active holoenzyme in solution. Benzoate and CPZ similarly modify the short-term cellular D-serine concentration but affect the cellular concentration of hDAAO differently. In conclusion, the different alteration of hDAAO conformation and stability by the ligands used represents a further parameter to take into consideration during the development of new drugs to cope schizophrenia.
Collapse
Affiliation(s)
- Laura Caldinelli
- Dipartimento di Biotecnologie e Scienze Molecolari, Università degli studi dell'Insubria, via J.H. Dunant 3, 21100 Varese
| | | | | | | | | | | | | | | |
Collapse
|